(Q46407140)

21 December 2017

title

Ten years of anti-vascular endothelial growth factor therapy (English)

1 reference

21 December 2017

0 references

Napoleone Ferrara

1

1 reference

21 December 2017

Anthony P Adamis

series ordinal

2

1 reference

21 December 2017

publication date

18 January 2016

1 reference

21 December 2017

Nature Reviews Drug Discovery

published in

1 reference

21 December 2017

volume

15

1 reference

21 December 2017

issue

6

1 reference

21 December 2017

page(s)

385-403

1 reference

21 December 2017

https://scigraph.springernature.com/pub.10.1038/nrd.2015.17

exact match

0 references

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

VEGF and the quest for tumour angiogenesis factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Tumor angiogenesis: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Regulators of Angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Vascular endothelial growth factor is a secreted angiogenic mitogen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Vascular endothelial growth factor: basic science and clinical progress

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Vascular endothelial growth factor and age-related macular degeneration: from basic science to therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy

21 January 2018

2 references

https://api.crossref.org/works/10.1038%2FNRD.2015.17

21 January 2018

12 December 2020

Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

VEGF-Trap: a VEGF blocker with potent antitumor effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

VEGF receptor signalling - in control of vascular function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Lymphangiogenesis in development and human disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

The biology of VEGF and its receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Binding to the extracellular matrix and proteolytic processing: two key mechanisms regulating vascular endothelial growth factor action

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Programmed translational readthrough generates antiangiogenic VEGF-Ax

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Angiogenesis in ischemic and neoplastic disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

The von Hippel-Lindau tumour suppressor protein: O2 sensing and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Binding sites for vascular endothelial growth factor are localized on endothelial cells in adult rat tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Corneal avascularity is due to soluble VEGF receptor-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Molecular control of endothelial cell behaviour during blood vessel morphogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Essential role of Flk-1 (VEGF receptor 2) tyrosine residue 1173 in vasculogenesis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Predominant role of endothelial nitric oxide synthase in vascular endothelial growth factor-induced angiogenesis and vascular permeability

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Selective requirement for Src kinases during VEGF-induced angiogenesis and vascular permeability

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

VEGF controls endothelial-cell permeability by promoting the beta-arrestin-dependent endocytosis of VE-cadherin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

VEGFR2 induces c-Src signaling and vascular permeability in vivo via the adaptor protein TSAd.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Molecular regulation of vessel maturation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Why are tumour blood vessels abnormal and why is it important to know?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Intravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Vascular endothelial growth factor signaling pathways: therapeutic perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

VEGF-targeted therapy: mechanisms of anti-tumour activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

The vascular endothelial growth factor proteins: identification of biologically relevant regions by neutralizing monoclonal antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Cross-species vascular endothelial growth factor (VEGF)-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Replacing the complementarity-determining regions in a human antibody with those from a mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Targeting VEGF-A to treat cancer and age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Angiogenesis as a therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

A randomized trial of bevacizumab for newly diagnosed glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Improved survival with bevacizumab in advanced cervical cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Incorporation of bevacizumab in the primary treatment of ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Hearing improvement after bevacizumab in patients with neurofibromatosis type 2

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Anti-VEGF therapies in the clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Bevacizumab in stage II-III colon cancer: 5-year update of the National Surgical Adjuvant Breast and Bowel Project C-08 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Personalizing colon cancer adjuvant therapy: selecting optimal treatments for individual patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

The discovery of receptor tyrosine kinases: targets for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Tyrphostins and other tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Crystal structure of the kinase domain of human vascular endothelial growth factor receptor 2: a key enzyme in angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Tyrosine kinase inhibitors: views of selectivity, sensitivity, and clinical performance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Therapies directed at vascular endothelial growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Preclinical and clinical development of the oral multikinase inhibitor sorafenib in cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Sorafenib in advanced clear-cell renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Sorafenib in advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

An update on clinical trials of targeted therapies in thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Sunitinib malate for the treatment of pancreatic neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Pazopanib versus sunitinib in metastatic renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Sunitinib plus paclitaxel versus bevacizumab plus paclitaxel for first-line treatment of patients with advanced breast cancer: a phase III, randomized, open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phase III study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Fluorouracil, leucovorin, and irinotecan plus either sunitinib or placebo in metastatic colorectal cancer: a randomized, phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Aflibercept in the treatment of patients with metastatic colorectal cancer: latest findings and interpretations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Aflibercept and Docetaxel versus Docetaxel alone after platinum failure in patients with advanced or metastatic non-small-cell lung cancer: a randomized, controlled phase III trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Ziv-aflibercept: binding to more than VEGF-A--does more matter?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

PlGF blockade does not inhibit angiogenesis during primary tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, doubl

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Controlling escape from angiogenesis inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Phase 1 dose-escalation study of the antiplacental growth factor monoclonal antibody RO5323441 combined with bevacizumab in patients with recurrent glioblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Targeting placental growth factor/neuropilin 1 pathway inhibits growth and spread of medulloblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Targeting the ANGPT-TIE2 pathway in malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Role of angiopoietin-2 in adaptive tumor resistance to VEGF signaling blockade.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Function blocking antibodies to neuropilin-1 generated from a designed human synthetic antibody phage library

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Anti-EGFL7 antibodies enhance stress-induced endothelial cell death and anti-VEGF efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Predictive impact of circulating vascular endothelial growth factor in four phase III trials evaluating bevacizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Biomarkers to predict the clinical efficacy of bevacizumab in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

The search for biomarkers to direct antiangiogenic treatment in epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Direct evidence that bevacizumab, an anti-VEGF antibody, up-regulates SDF1alpha, CXCR4, CXCL6, and neuropilin 1 in tumors from patients with rectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Biomarkers of response and resistance to antiangiogenic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Identification and analysis of in vivo VEGF downstream markers link VEGF pathway activity with efficacy of anti-VEGF therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Genetic variability of VEGF pathway genes in six randomized phase III trials assessing the addition of bevacizumab to standard therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Targeting the tumour vasculature: insights from physiological angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Bv8 regulates myeloid-cell-dependent tumour angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Pathways mediating VEGF-independent tumor angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Anti-VEGF antibody therapy does not promote metastasis in genetically engineered mouse tumour models

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Differential drug class-specific metastatic effects following treatment with a panel of angiogenesis inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Nintedanib Is a Highly Effective Therapeutic for Neuroendocrine Carcinoma of the Pancreas (PNET) in the Rip1Tag2 Transgenic Mouse Model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Disease course patterns after discontinuation of bevacizumab: pooled analysis of randomized phase III trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Modeling and predicting clinical efficacy for drugs targeting the tumor milieu

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Observations on the choroidal circulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Detection of vascular endothelial growth factor messenger RNA and vascular endothelial growth factor-like activity in proliferative diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Vascular endothelial growth factor is sufficient to produce iris neovascularization and neovascular glaucoma in a nonhuman primate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Intrachoroidal neovascularization in transgenic mice overexpressing vascular endothelial growth factor in the retinal pigment epithelium

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Vascular endothelial growth factor a in intraocular vascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Pegaptanib for neovascular age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Preclinical safety evaluation of rhuMAbVEGF, an antiangiogenic humanized monoclonal antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Fc receptors and their interactions with immunoglobulins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Ophthalmic timolol: plasma concentration and systemic cardiopulmonary effects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Antibody humanization using monovalent phage display

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

VEGF and the Fab fragment of a humanized neutralizing antibody: crystal structure of the complex at 2.4 A resolution and mutational analysis of the interface

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Ranibizumab for neovascular age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Ranibizumab versus verteporfin for neovascular age-related macular degeneration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Significant improvements in near vision, reading speed, central visual field and related quality of life after ranibizumab treatment of wet age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Rationale for the diabetic retinopathy clinical research network treatment protocol for center-involved diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Improved vision-related function after ranibizumab for macular edema after retinal vein occlusion: results from the BRAVO and CRUISE trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Long-term outcomes in patients with retinal vein occlusion treated with ranibizumab: the RETAIN study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial results

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Monthly versus as-needed ranibizumab injections in patients with retinal vein occlusion: the SHORE study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Ranibizumab and bevacizumab for neovascular age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Current phase 1/2 research for neovascular age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Inhibition of platelet-derived growth factor B signaling enhances the efficacy of anti-vascular endothelial growth factor therapy in multiple models of ocular neovascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Twenty-four-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Incidence of legal blindness from age-related macular degeneration in denmark: year 2000 to 2010.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Racial variations in causes of vision loss in nursing homes: The Salisbury Eye Evaluation in Nursing Home Groups (SEEING) Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Global prevalence and major risk factors of diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Burden of illness of diabetic macular edema: literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Long-term visual outcomes of intravitreal ranibizumab treatment for wet age-related macular degeneration and effect on blindness rates in south-east Scotland

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

VEGF Trap-Eye for macular oedema secondary to central retinal vein occlusion: 6-month results of the phase III GALILEO study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Intravitreal aflibercept for diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Vascular endothelial growth factor B, a novel growth factor for endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Identification of a c-fos-induced gene that is related to the platelet-derived growth factor/vascular endothelial growth factor family

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Sunitinib in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Blocking neuropilin-2 function inhibits tumor cell metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Angiogenesis-independent endothelial protection of liver: role of VEGFR-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Expression of a functional VEGFR-1 in tumor cells is a major determinant of anti-PlGF antibodies efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

ANTI-VEGF TREATMENT IN NEOVASCULAR AGE–RELATED MACULAR DEGENERATION

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Transplacental carcinogenesis by stilbestrol

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Vascular permeability factor, an endothelial cell mitogen related to PDGF

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Vascular endothelial growth factor (VEGF) and its receptors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic br

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Sunitinib Does Not Accelerate Tumor Growth in Patients with Metastatic Renal Cell Carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Patients With Proneural Glioblastoma May Derive Overall Survival Benefit From the Addition of Bevacizumab to First-Line Radiotherapy and Temozolomide: Retrospective Analysis of the AVAglio Trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Synthesis and secretion of vascular permeability factor/vascular endothelial growth factor by human retinal pigment epithelial cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Once-weekly intraocular injections of ganciclovir for maintenance therapy of cytomegalovirus retinitis: clinical and ocular outcome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Future of monoclonal antibodies in the treatment of hematologic malignancies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Estimated cases of legal blindness and visual impairment avoided using ranibizumab for choroidal neovascularization: non-Hispanic white population in the United States with age-related macular degeneration

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

Age-related macular degeneration

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.17

The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors

31 March 2020

1 reference

12 December 2020

Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies.

1 reference

12 December 2020

Quantitation and physiological characterization of angiogenic vessels in mice: effect of basic fibroblast growth factor, vascular endothelial growth factor/vascular permeability factor, and host microenvironment

1 reference

12 December 2020

Complete inhibition of rhabdomyosarcoma xenograft growth and neovascularization requires blockade of both tumor and host vascular endothelial growth factor.

1 reference

12 December 2020

Purification and NH2-terminal amino acid sequence of guinea pig tumor-secreted vascular permeability factor.

1 reference

12 December 2020

Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders

1 reference

12 December 2020

FLT4 receptor tyrosine kinase contains seven immunoglobulin-like loops and is expressed in multiple human tissues and cell lines

1 reference

12 December 2020

Flk-1 as a target for tumor growth inhibition.

1 reference

12 December 2020

Prevalence of age-related macular degeneration in the United States

1 reference

12 December 2020

Targeting MET and EGFR in NSCLC-what can we learn from the recently reported phase III trial of onartuzumab in combination with erlotinib in advanced non-small cell lung cancer?

1 reference

12 December 2020

Retinal neovascularization

1 reference

12 December 2020

A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases

1 reference

12 December 2020

Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration.

1 reference

12 December 2020

VEGF-initiated blood-retinal barrier breakdown in early diabetes.

1 reference

12 December 2020

Ramucirumab, a fully human mAb to the transmembrane signaling tyrosine kinase VEGFR-2 for the potential treatment of cancer.

1 reference

12 December 2020

Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family

1 reference

12 December 2020

Pazopanib versus sunitinib in renal cancer

1 reference

12 December 2020

Prolonged blockade of VEGF receptors does not damage retinal photoreceptors or ganglion cells

1 reference

12 December 2020

Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR

1 reference

12 December 2020

The second immunoglobulin-like domain of the VEGF tyrosine kinase receptor Flt-1 determines ligand binding and may initiate a signal transduction cascade

1 reference

12 December 2020

Complete inhibition of angiogenesis and growth of microtumors by anti-vascular endothelial growth factor neutralizing antibody: novel concepts of angiostatic therapy from intravital videomicroscopy.

1 reference

12 December 2020

VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma

1 reference

12 December 2020

Human vascular permeability factor. Isolation from U937 cells

1 reference

12 December 2020

Identification of a new endothelial cell growth factor receptor tyrosine kinase

1 reference

12 December 2020

In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.

1 reference

12 December 2020

Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model.

1 reference

12 December 2020

Cloning and mRNA expression of vascular endothelial growth factor in ischemic retinas of Macaca fascicularis.

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRD.2015.17

1 reference

21 December 2017

1 reference

21 December 2017